Overexpression of cofactor of BRCA1 in HepG2 cells: A step towards understanding the role of COBRA1 in hepatocellular carcinoma by Masad, Razan Jamil
American University in Cairo 
AUC Knowledge Fountain 
Theses and Dissertations 
2-1-2016 
Overexpression of cofactor of BRCA1 in HepG2 cells: A step 
towards understanding the role of COBRA1 in hepatocellular 
carcinoma 
Razan Jamil Masad 
Follow this and additional works at: https://fount.aucegypt.edu/etds 
Recommended Citation 
APA Citation 
Masad, R. (2016).Overexpression of cofactor of BRCA1 in HepG2 cells: A step towards understanding the 
role of COBRA1 in hepatocellular carcinoma [Master’s thesis, the American University in Cairo]. AUC 
Knowledge Fountain. 
https://fount.aucegypt.edu/etds/552 
MLA Citation 
Masad, Razan Jamil. Overexpression of cofactor of BRCA1 in HepG2 cells: A step towards understanding 
the role of COBRA1 in hepatocellular carcinoma. 2016. American University in Cairo, Master's thesis. AUC 
Knowledge Fountain. 
https://fount.aucegypt.edu/etds/552 
This Thesis is brought to you for free and open access by AUC Knowledge Fountain. It has been accepted for 
inclusion in Theses and Dissertations by an authorized administrator of AUC Knowledge Fountain. For more 
information, please contact mark.muehlhaeusler@aucegypt.edu. 
 
 
 
 
 
 
 
 
  
Overexpression of Cofactor of BRCA1 in HepG2 Cells: A Step Towards 
Understanding the Role of COBRA1 in Hepatocellular Carcinoma 
 
A Thesis Submitted to the 
Biotechnology Master’s Program  
In partial fulfilment of the requirements for the  
Degree of Master of Science 
 
By: Razan Jamil Masad  
(Under the supervision of Dr. Asma Amleh)  
 
December/2016  
 ii 
 
The American University in Cairo 
School of Sciences and Engineering (SSE) 
 
Overexpression of Cofactor of BRCA1 in HepG2 Cells: A Step Towards 
Understanding the Role of COBRA1 in Hepatocellular Carcinoma 
 
A Thesis Submitted by 
Razan Jamil Masad 
Submitted to the Biotechnology Master’s Program 
December 2016 
 
In partial fulfilment of the requirements for the degree of 
Master of Science in Biotechnology 
Has been approved by 
 
 Thesis Committee Supervisor/Chair  
_______________________________________________   
Affiliation ______________________________________  
Thesis Committee Reader/Examiner  
______________________________________________   
Affiliation _____________________________________   
Thesis Committee Reader/Examiner  
______________________________________________   
Affiliation ______________________________________   
Thesis Committee Reader/External Examiner  
______________________________________________   
Affiliation _____________________________________   
  ________________       _____________       ______________         
Dept. Chair/Director      Date              Dean         Date  
 iii 
 
 
 
 
 
 
 
 
 
 
 
DEDICATION 
 
To my dear mother, father and my beloved family for their continuous 
support, love and prayers throughout the journey. To my dearest friends 
for being always by my side and for being my stress release and laughter 
when needed. Without all of your care and support, I wouldn’t have been 
able to complete this process. I love you all 
  
 iv 
 
ACKNOWLEDGEMENTS 
 
I would like to thank all the people who contributed to this work. First and foremost, 
I would like to express my deepest gratitude to my thesis supervisor Dr.Asma Amleh 
for her continuous guidance and support during my thesis work. I would like to thank 
her for supporting my research and allowing me to grow as a scientist. I’m truly 
thankful for all the time and effort she spent on guiding me. I would also like to thank 
all of the professors in the Biotechnology program who have taught me and provided 
me with a strong base in Biotechnology. Seeing how much enthused and passionate 
they are about their work has been always a motivation for me. 
I sincerely thank Dr Rong Li for providing the pCMV5-HCOBRA1 expression 
plasmid, and Dr.Ahmed Osman for providing the pEGFP-N1 expression plasmid that 
were used in this work. I would also like to thank Amgad Ouf for his continuous help 
and support whenever needed. My deep appreciation goes to my colleagues for always 
offering help and advice which has helped me a lot in my work. I’m sincerely grateful 
to Nahla Osama, Ahmed Gad, Noha Saad, Heba Shawer, Eman El Zeneini, Myret 
Ghabriel, Laila Ziko, Eman Rabie and Nahla Hussein for their scientific advice and 
help in the laboratory work. I’m so grateful to Ahmed Safwat for being by my side 
throughout my graduate studies. I would also like to thank all the lab members for 
making the working environment friendly and interactive, and for all the inspiring 
discussions we had during the meetings which have certainly resulted in a productive 
knowledge transfer between us.  
I would also like to take this opportunity to express my extreme appreciation for the 
funding sources that allowed me to pursue my graduate studies. I would like to express 
much gratitude to Queen Rania Al-Abdullah ’91 Fellowship sponsors for funding my 
studies. I am really honoured to be the recipient of this scholarship and extremely 
grateful for all the efforts made by Her Majesty in enhancing the educational 
opportunities for Jordanians. My sincere thanks go to all the AUC Alumni in Jordan 
members for supporting this fellowship. My special appreciation goes to Basel 
Abuqura who believed in me and encouraged me since the beginning. 
Last but not least, I would like to express much gratitude to the AUC for providing 
the research grant that funded this research and for partially funding my studies.  
 v 
 
ABSTRACT 
The American University in Cairo 
Overexpression of Cofactor of BRCA1 in HepG2 Cells: A Step Towards 
Understanding the Role of COBRA1 in Hepatocellular Carcinoma 
By Razan Jamil Masad 
Under the supervision of Dr. Asma Amleh 
Cofactor of BRCA1 (COBRA1) is a BRCA-1 interacting protein that represents one of 
the four subunits of the negative elongation factor (NELF) complex. NELF is known 
by its ability to stall RNA Polymerase II during the early phase of transcription 
elongation, resulting in repressed transcription of several genes including ones 
associated with tumorigenesis of different cancer types. While it was found to be down-
regulated in breast cancer, COBRA1 was found to be up-regulated in the upper 
gastrointestinal carcinoma. Up to date, the role of COBRA1 in hepatocellular 
carcinoma (HCC) is unclear. We have previously demonstrated that silencing of 
COBRA1 in the HCC cell line HepG2, significantly inhibited the proliferation and 
migration potentials of the cells. Here, we investigated the effect of ectopic expression 
of COBRA1 on HepG2 cells proliferation and migration. Lipofectamine 3000 was used 
to transfect HepG2 cells with a pCMV5-HCOBRA1 plasmid. The transfection 
efficiency was determined by the percentage of EGFP positive cells (pEGFP-N1+) via 
fluorescent microscope, semi-quantitative RT-PCR as well as western blot analysis. 
The cells proliferation and migration following COBRA1 overexpression were 
assessed using the trypan blue dye exclusion method and the wound-healing assays 
respectively. The semi-quantitative RT-PCR was used to analyse the mRNA 
expressions of the other NELF subunits, TFF1 and TFF3 genes, which are known to be 
regulated by the NELF complex, as well as other tumorigenesis related genes. Our 
results revealed that COBRA1 transfected cells exhibited a comparable proliferation 
and migration rates to non-transfected cells. These results were accompanied by an 
insignificant effect of COBRA1 overexpression on the levels of the proliferation 
marker; Ki-67 and the anti-apoptotic gene; survivin. Also, the mRNA levels of the other 
NELF subunits, TFF1 and TFF3 were found to be comparable among all the tested 
groups. Collectively, our results suggest that the proposed involvement of COBRA1 in 
HCC is supported by and dependent on the assembly of the active NELF complex, 
which requires the expression of all four NELF subunits. Moreover, COBRA1 
mediated role in HCC tumorigenesis might be due to mechanisms and regulatory 
pathways other than the ones examined here. However, further studies are required to 
confirm these notions. 
  
 vi 
 
 
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS ................................................................................................ viii 
LIST OF TABLES ................................................................................................................... xi 
LIST OF FIGURES................................................................................................................. xii 
CHAPTER 1. LITERATURE REVIEW .................................................................................. 1 
1.1. Hepatocellular Carcinoma .............................................................................................. 1 
1.1.1 Incidence and epidemiology ..................................................................................... 1 
1.1.2 Risk factors and prevention ...................................................................................... 2 
1.1.3 Surveillance and diagnosis ....................................................................................... 5 
1.1.4 Staging and therapeutic management ....................................................................... 5 
1.1.5 Molecular alterations in HCC .................................................................................. 8 
1.2. Cofactor of BRCA1 ...................................................................................................... 10 
1.2.1 Identification, Structure and Function .................................................................... 10 
1.2.2 COBRA1 role in transcription regulation .............................................................. 12 
1.2.3 COBRA1 interaction with other transcription factors ............................................ 14 
1.2.4 Role in Cancer ........................................................................................................ 17 
1.2.5 Role in Hepatocellular Carcinoma ......................................................................... 19 
HYPOTHESIS AND SPECIIC OBJECTIVES ...................................................................... 19 
CHAPTER 2. MATERIALS AND METHODS ..................................................................... 20 
2.1. Cell Culture .............................................................................................................. 20 
2.2. Viable Cell Count ..................................................................................................... 20 
2.3. Plasmid constructs .................................................................................................... 20 
2.5. Restriction digestion ................................................................................................. 22 
2.6. Colony PCR ............................................................................................................. 23 
2.7. Cell transfection ....................................................................................................... 23 
2.8. RNA Extraction ........................................................................................................ 24 
2.9. Reverse Transcription Polymerase Chain Reaction (RT-PCR) ................................ 25 
2.10. Western blot Analysis ............................................................................................ 26 
2.11. Wound-healing assay ............................................................................................. 27 
2.12. Statistical analysis .................................................................................................. 28 
CHAPTER 3. RESULTS ........................................................................................................ 29 
3.1. Confirmation of plasmids identities ............................................................................. 29 
3.2. Optimal protocol for HepG2 cells transfection ............................................................ 30 
3.3. COBRA1 transfection efficiency and effect on cells morphology ............................... 34 
3.4. mRNA and protein levels of the NELF subunits following COBRA1 overexpression 36 
3.5. TFF1 and TFF3 mRNA levels following COBRA1 overexpression ........................... 37 
 vii 
 
3.6. COBRA1 overexpression effect on the proliferation potential of HepG2 cells ........... 38 
3.7. COBRA1 Overexpression effect on the migratory potential of HepG2 cells .............. 39 
3.8. COBRA1 Overexpression effect on the survivin gene expression .............................. 40 
CHAPTER 4. DISCUSSION .................................................................................................. 42 
4.1. Co-dependent stability of the NELF subunits .............................................................. 42 
4.2. Trefoil factors (TFF1 & TFF3) expressions relative to COBRA1 overexpression ...... 44 
4.3. COBRA-1 overexpression effect on the proliferation potential of HepG2 cells .......... 45 
4.4. COBRA1 overexpression effect on the migratory potential of HepG2 cells ............... 47 
4.5. COBRA1 overexpression effect on the mRNA expression of survivin ....................... 48 
CONCLUSION ....................................................................................................................... 50 
FUTURE DIRECTIONS ........................................................................................................ 51 
REFERENCES ........................................................................................................................ 52 
 
  
 viii 
 
LIST OF ABBREVIATIONS 
 
AASLD American Association for the Study of Liver Diseases 
AFP Alpha-Fetoprotein 
ANOVA Analysis of Variance 
AP-1 Activator Protein-1 
AR Androgen Receptor1 
ARID1 AT-Rich Interaction Domain 1 
ARID2 AT-Rich Interaction Domain 2 
BIRC5 Baculoviral Inhibitor of Apoptosis Protein Repeat- Containing 5 
Bps Base Pairs 
BRCA1 Breast Cancer Type 1 Susceptibility Protein 
BRCT1 BRCA1 C-terminal 1 
BRCT2 BRCA1 C-terminal 2 
CAP2 Cyclase-Associated Protein2 
CDKN2A Cyclin-Dependent Kinase Inhibitor 2A 
ChIP Chromatin Immunoprecipitation  
COBRA1 Cofactor of BRCA1 
CTD C-Terminal Domains 
CTNNB1 Catenin Beta 1 
DEC1  Deleted in Esophageal Cancer 1 
DEPC Diethylpyrocarbonate 
DSIF DRB Sensitivity-Inducing Factor 
E-cadherin Epithelial Cadherin 
EGF Epidermal Growth Factor 
ERα Estrogen Receptor-Alpha 
ESCs Embryonic Stem Cells 
ESMO European Society for Medical Oncology 
FBS Fetal Bovine Serum 
GFP Green Florescent Protein  
GPC3 Glypican-3 
GR Glucocorticoid Receptor 
HBV Hepatitis B Virus 
 ix 
 
HCC Hepatocellular Carcinoma 
HCV Hepatitis C Virus 
HepG2 Well Differentiated Human Hepatocellular Carcinoma- Cell Line 
Hr Hour 
Hsp70 Heat Shock Protein 70 
HTA Hepatoma-Associated Gene 
IAP Inhibitor of Apoptosis 
IFN-a Interferon Alpha 
KLF5  Kruppel-Like Factor 5 
LBD Ligand Binding Domain 
LT Liver Transplantation 
MAPK Mitogen-Activated Protein Kinases 
MECC Middle East Cancer Consortium 
MELD Model for End-stage Liver Disease 
Mins Minutes 
MLL Mixed-lineage Leukemia Protein 2 
NAFLD Nonalcoholic Fatty Liver Disease 
NELF Negative Elongation Factor 
NR Nuclear Receptors 
PBS Phosphate-Buffered Saline 
PBST 0.01% Tween-20 in 1X PBS 
PCR Polymerase Chain Reaction 
PDGFRs Platelet-derived Growth Factor Receptors 
PI3K Phosphoinositide 3-kinase 
PRB Progesterone Receptor B 
P-TEFB Positive Transcription Elongation Factor B 
RFA Radiofrequency Ablation 
RNAPII RNA Polymerase II 
RT-PCR Reverse Transcription Polymerase Chain Reaction 
SD Standard Deviation 
SDS Sodium Dodecyl Sulfate 
SEER Surveillance, Epidemiology and End Results Populations 
Sox2 SRY (sex determining region Y)-box 2 
 x 
 
SK-BR-3  Metastatic Human breast Carcinoma Cell Line 
SRPK  SR Protein-Specific Kinase  
STAT3  Signal Transducer and Activator of Transcription 3 
T47D Metastatic Human Breast Carcinoma Cell Line 
TACE Transarterial Chemoembolization 
TFF2 Trefoil Factor 2 
TFF3 Trefoil Factor 3 
TGF-β1 Transforming Growth Factor-β1 
UCSF University of California San Francisco 
UGCs Upper Gastrointestinal Cancer 
VEGF Vascular Endothelial Growth Factor 
WHSC2 Wolf-Hirschhorn Syndrome Candidate 2 
WT Wild Type 
μls Microliters 
 
  
 xi 
 
LIST OF TABLES 
Table 1. RT-PCR primer sequences, annealing temperatures, cycle numbers and 
amplicon sizes (F: forward primer, R: reverse primer, bp: base pair) ......................... 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xii 
 
LIST OF FIGURES 
Figure 1. Confirmation of plasmids identities ............................................................ 30 
Figure 2. Optimization of COBRA1 transfection in HepG2 cells .............................. 33 
Figure 3. COBRA1 significantly overexpressed at both mRNA and protein levels .. 35 
Figure 4. The morphology pattern of HepG2 cells following COBRA1 
overexpression. ............................................................................................................ 35 
Figure 5. The expression of NELF-A, NELFC/D and NELF-E subunits upon 
COBRA1 overexpression ............................................................................................ 36 
Figure 6. TFF1 and TFF3 expressions following COBRA1 overexpression ............. 37 
Figure 7. The proliferation potential of HepG2 cells following COBRA1 
overexpression ............................................................................................................. 39 
Figure 8. The migratory potential of HepG2 cells following COBRA1 
overexpression. ............................................................................................................ 40 
Figure 9. survivin mRNA expression following COBRA1 overexpression. .............. 41 
 1 
 
CHAPTER 1. LITERATURE REVIEW 
 
1.1. Hepatocellular Carcinoma 
1.1.1 Incidence and epidemiology 
Hepatocellular carcinoma (HCC) is the most frequent type of liver cancer, 
accounting for more than 90% of primary liver cancer cases (Bodzin & Busuttil, 2015; 
Liver, 2012). Currently, HCC ranks the sixth most frequent cancer and the second 
leading cause of cancer-related deaths worldwide, where almost 746000 people die 
from HCC each year(Ashtari, Pourhoseingholi, Sharifian, & Zali, 2015; Flores & 
Marrero, 2014). 
The frequency of HCC increases with age. In fact, most of the reported cases are 
diagnosed at the age of 65 years or more (Waghray, Murali, & Menon, 2015). Having 
a three times higher incidence rate in men than in women, HCC is considered a male 
predominant cancer (Howlader, Noone, & Krapcho, 2015). 
An extensive variation in the world-wide distribution of HCC has been remarkably 
observed. While 3 out of 100 000 are infected with HCC in the western countries, more 
than 15 out of 100,000 are infected in other regions of the world, most of which are 
noticed in the developing countries (Siegel, Miller, & Jemal, 2015). In Egypt, HCC 
incidence is very high compared to other countries. According to the MECC (Middle 
East Cancer Consortium), HCC rate among Egyptian men was 7 times higher than other 
MECC countries (Cyprus, Palestine & Jordan) and 3 times higher than the US SEER 
(Surveillance, Epidemiology and End results populations). Among females, however, 
HCC rate was 3 times higher than other MECC countries and more than twice the US 
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SEER rate (Freedman, Edwards, Ries, & Young, 2006). The high occurrence of HCC 
in Egypt is due to the high number of HCV infections, where almost 14% of the 
Egyptian population is HCV-infected(Gomaa, Hashim, & Waked, 2014; Shelbaya, 
Kuznik, Salem, Mankola, & Sadik, 2015) 
1.1.2 Risk factors and prevention 
Several factors have been reported to be involved in HCC development. These 
factors include; liver cirrhosis, chronic hepatitis B virus (HBV) infection, chronic 
hepatitis C virus (HCV) infection, hereditary hemochromatosis, aflatoxin consumption, 
alcoholism, diabetes as well as obesity (Flemming, Yang, Vittinghoff, Kim, & Terrault, 
2014). 
Being presented in almost (80-90%) of HCC-infected individuals, liver cirrhosis is 
considered as the main risk factor for HCC (El-Serag, 2012a). Mainly, liver cirrhosis 
results from viral hepatitis infection, Alcohol-related liver disease, Nonalcoholic fatty 
liver disease (NAFLD) as well as aflatoxin consumption (Flemming et al., 2014). 
Despite the wide regional variations in HCC etiology and distribution, chronic 
infections with hepatitis B and C represent the majority of HCC cases globally (El-
Serag, 2012a). HBV infection results in acute and chronic liver disease, increasing by 
this the risk of developing HCC(El-Serag, 2012a). Several mechanisms for the 
progression from HBV to HCC have been proposed. For instance, both the 
inflammation and necrosis that result from HBV may cause alterations in the 
hepatocyte’s genetic expressions, resulting in induction of the malignancy(Rossner, 
1992). In addition, viral integration in to the liver cells results in a chromosomal 
instability and defected cellular replication leading to the development of 
HCC(Brechot, Pourcel, Louise, Rain, & Tiollais, 1980; Kremsdorf, Soussan, Paterlini-
Brechot, & Brechot, 2006). 
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Upon introducing the obligatory universal HBV vaccination at birth, a decline of the 
HBV-related HCC cases was observed. For instance, following implementation of the 
Taiwan universal vaccination program, a significant reduction in the HCC annual 
incidence from 0.70 to 0.36 per 100,000 children was reported within a 10-year period 
(Ni et al., 2007). However, since this mandatory vaccination was implemented in the 
early 1980s, most of the adults over the age of 30 are not vaccinated and are at high 
risk of developing HCC(Pol, 2015). Thus, HBV prevention among adults is carried out 
through focusing on anti-viral treatments such as interferon alpha (IFN-a). In fact, IFN-
a was shown to decrease the risk of developing HCC by a percentage of 6.4% (Cammà, 
Giunta, Andreone, & Craxı̀, 2001). 
HCV infection leads to an inflammatory hepatocyte damage from oxidative stress, 
indorsing by this liver cirrhosis and resulting in HCC development (Parola & Robino, 
2001). Currently, almost 40-50% of HCC cases are attributed to chronic HCV 
infections (Bruix & Sherman, 2005; Omar, Abou-Alfa, Khairy, & Omar, 2013). In fact, 
HCV-infected individuals have 17-times higher risk of developing HCC compared to 
HCV-negative individuals (Tanaka et al., 2006). Usually, HCV antiviral treatments are 
used to decrease the risk of the development of HCV-based HCC. Many studies have 
shown that responders to treatment with interferon (IFN) have a lower risk of 
developing HCC compared to non-responders and not-treated patients (Yoshida et al., 
1999). 
Alcohol related liver disease and Nonalcoholic fatty liver disease (NAFLD) also 
contributes to the development of HCC(Waghray et al., 2015). The molecular strategy 
by which alcoholism leads to HCC is not well addressed. However, several evidences 
indicate that it might be through indorsing altered DNA methylation, reduction in the 
 4 
liver’s retinoic acid level, oxidative stress as well as chromosomal loss (Bruix, Gores, 
& Mazzaferro, 2014).  
NAFLD incidence is increasing due to the increasing numbers of obesity and 
diabetes worldwide. NAFLD is characterized by the fatty livers of infected individuals 
as well as inflammation and fibrosis(Petta et al., 2015; Pinzani, 2015). Almost 40% of 
NAFLD patients develop fibrosis, in which 9% of them progress to cirrhosis, resulting 
in the development of HCC as a complication (Adams et al., 2005; J. M. Hui et al., 
2003).  
Alfatoxin-B1 consumption is also considered as one of the major contributors to 
HCC development. Aflatoxins are mycotoxins produced by the Aspergillus fungus and 
Aspergillus parasiticus. They are mostly found on improperly stored food including 
rice, corn, peanuts and wheat (El-Serag, 2012a). The ability of aflatoxins to induce 
hepatocarcinogenesis was shown in several animal experiments. One study has 
revealed that when ingested, aflatoxin metabolizes to an active aflatoxin B1-exo-8, 9-
epoxide. As a result, it binds to the DNA and causes DNA damage. This eventually 
results in the development of mutations in the tumor suppressor gene p53 (p53 249 ser), 
which will in turn induce the development of HCC (Garner, Miller, & Miller, 1972). 
In fact, these mutations have been observed in almost 30-60 % of HCC patients in 
aflatoxin-endemic regions (TURNER et al., 2002). In Egypt, Aflatoxin B1 
consumption is considered as one of the main risk factors of HCC development (Omar 
et al., 2013).  
Both obesity and diabetes are common risk factors of HCC. In fact, obese patients 
are100-times at risk of developing HCC than non-obese patients (Chen et al., 2008). 
Likewise, Diabetes is related to a 2-3 fold increase in the risk of developing HCC(J. 
Davila, Morgan, Shaib, McGlynn, & El-Serag, 2005).  
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 Other less common risk factors for HCC development include; Wilson’s disease, 
glycogen storage disease, autoimmune hepatitis, hereditary hemochromatosis and 
alpha 1-anti trypsin deficiency (Waghray et al., 2015). 
1.1.3 Surveillance and diagnosis 
HCC patients diagnosed at early stages have higher survival rates compared to those 
diagnosed with advanced stages (Bruix & Llovet, 2009). Therefore, standardized 
surveillance is recommended for patients at risk of HCC development. Surveillance 
involves a repeated screening of patients at high risk of HCC. The effectiveness of 
surveillance depends on the incidence of HCC in the target population as well as the 
availability of effective diagnostic tests and treatments (Verslype, Rosmorduc, 
Rougier, & Group, 2012). 
 Previous studies have indicated that surveillance increases the survival when the 
yearly rate of HCC is more than 1.5% of the target population (Sarasin, Giostra, & 
Hadengue, 1996). According to the guidelines indorsed by the American association 
for the study of liver diseases (AASLD) and the European society for medical oncology 
(ESMO), HCC Surveillance includes a mandatory  abdominal ultrasound screening 
every 6 months (El-Serag, 2012b; Verslype et al., 2012).  
1.1.4 Staging and therapeutic management 
Currently, there are several treatment options available for HCC patients. These 
treatments could be either curative or palliative. The curative treatment options include; 
liver transplantation, surgical resection and local ablation. These options have shown a 
5-year survival rates of up to 75% (El-Serag, Marrero, Rudolph, & Reddy, 2008; Lin, 
Hoffmann, & Schemmer, 2012). Nonetheless, due to the small number of eligible 
patients to such treatments (less than 20%), most of the patients are exposed to 
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palliative treatments such as transarterial chemoembolization as well as chemotherapy 
(Clark et al., 2005; J. A. Davila, Duan, McGlynn, & El-Serag, 2012). 
The choice of the optimal therapy is decided according to the tumour stage.  
Currently, several staging systems have been developed to assess the stage of HCC. 
Both the Child-Pugh system and the model for end-stage liver disease (MELD) are 
used to evaluate the disease’s severity without dealing with the patient’s symptoms or 
performance (Bruix & Sherman, 2011; Jelic, Sotiropoulos, & Group, 2010).  
The Barcelona Clinic Liver Cancer (BCLC) staging system aims to link the disease 
stage with the patient’s performance, and it is the best to be used for selection of the 
proper therapy for HCC patients (Bruix & Sherman, 2011; J. Llovet & Ducreux, 2012). 
Usually, this system is used to identify patients with early-stage HCC (stage 0 and A) 
who are suitable for curative therapies, patients at intermediate or advanced stages 
(stages B&C) who are suitable for palliative treatments as well as patients with stage 
D HCC who have a very poor life expectancy (Lencioni, Chen, Dagher, & Venook, 
2010). 
Liver transplantation (LT) is the best possible curative treatment choice for HCC as 
well as the underlying cirrhosis(de Lope, Tremosini, Forner, Reig, & Bruix, 2012). It 
was shown that liver transplantation has resulted in a better overall survival rate 
compared to other options (Waghray et al., 2015). Thus, HCC patients with 
complicated cirrhosis should be assessed for their eligibility for such treatment. To 
assess the patient’s eligibility to liver transplantation, three selection criteria are used 
[Milan Criteria, University of California San Francisco (UCSF) and MELD 
(Mazzaferro et al., 1996; Pelletier et al., 2009). According to the Milan criteria, patients 
that have a single lesion( < 5 cm) or a maximum of 3 lesions (with each < 3cm), without 
any metastasis or vascular invasion are good candidates for LT (Mazzaferro et al., 
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2011). Patients meeting these criteria have shown a 4-year overall survival rate of 85% 
and a recurrence rate of less than12% (Kim & Hemming, 2009; Mazzaferro et al., 
2011). 
In 2011, the UCSF criteria has expanded the eligibility requirements, and included 
patients present with a single lesion (< 6.5 cm) or 3 lesions (with each one < 4.5 cm), 
and a total tumor diameter that is equal to or less than 8 cm. This selection criterion has 
shown comparable survival rates to the Milan criteria (Leung et al., 2004). 
The MELD score system aims to prioritize the patient’s assignments to the LT 
waiting list. Each HCC patient has a MELD score of 22 which increases every 3 
months. The MELD score is able to expect the mortality rates among patients with 
cirrhosis. However, due to its inability to predict the mortality rates among non-
cirrhotic HCC patients, an exception criteria was created to give extra points for HCC 
patients. In fact, applying this criteria have resulted in a rise of the number of HCC 
patients undergoing LT (Taniguchi, 2011). 
Surgical resection is considered as the best treatment choice for early stage-HCC 
patients having single lesions without any underlying cirrhosis (Vennarecci et al., 
2007). However, despite having a five-year survival rate of 70%, patients undergoing 
surgical resection have a high recurrence risk. In fact, an early recurrence within two 
years of surgery usually occurs due to an intrahepatic metastasis and local invasion. 
(Cucchetti et al., 2009; Xia et al., 2010). 
In the last decade, tumor ablation was used in treating HCC and has resulted in 
highly satisfactory results. Radiofrequency ablation (RFA) is considered as the best 
ablative therapy used for early stage HCC patients that are unsuitable for liver 
transplantation nor surgical resection (Nishikawa, Kimura, Kita, & Osaki, 2013). 
Patients with tumors of less than two cm diameter were reported to have the best results 
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when treated with RFA. In fact, these patients showed 90% chance of complete ablation 
upon receiving this treatment (Nishikawa et al., 2013). 
Transarterial chemoembolization (TACE) is the best therapy choice for patients with 
intermediate-stage HCC with a single lesion of less than 5 cm without any vascular 
invasion or hepatic metastasis (Forner, Llovet, & Bruix, 2012). It is based on the 
obstruction of blood supply to the tumor by introducing several chemotherapeutic 
agents such as doxorubicin, cisplatin and epirubcin (Forner et al., 2012). TACE- based 
therapy has resulted in a 25% decrease in tumor size in almost 40% of the patients(J. 
M. Llovet & Bruix, 2003). 
Systemic chemotherapy using cytotoxic drugs such as tamoxifen, cisplatin and 
everolimus have shown low response rates (Verslype et al., 2012). In fact, until now, 
Sorafinib was shown to be the only effective systemic therapy in advanced HCC 
(Bolondi et al., 2015). Sorafinib is an oral multi kinase inhibitor that works by blocking 
several cellular kinases involved in tumorigenesis such as vascular endothelial growth 
factor (VEGF) receptors, platelet-derived growth factor receptors (PDGFRs), c-KIT 
and RaslMAPK signalling pathways (S. Wilhelm et al., 2006; S. M. Wilhelm et al., 
2004). In a 2- phase III randomized placebo-controlled trials conducted in America, 
Europe and Asia, Sorafinib was found to have an anti-proliferative, anti-angiogenic as 
well as pro-apoptotic activity. In addition, using Sorafinib has resulted in 44% increase 
in the overall survival and a 3 months increase in the median survival among HCC 
patients (Cheng et al., 2009; J. M. Llovet et al., 2008). 
1.1.5 Molecular alterations in HCC 
Regardless of the availability of several surveillance and management tools of HCC, 
the exact molecular pathogenesis behind HCC remains unclear (Aravalli, Steer, & 
Cressman, 2008). Thus, research is focusing currently on identifying the key molecular 
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mechanisms underlying the development of HCC with the hope of developing new 
novel therapeutic strategies. 
Several oncogenes and tumor suppressors involved in the cell cycle and apoptosis 
are known to be associated with HCC development as a result of their mutations. p53 
gene is the most commonly mutated gene in HCC, where it was found to be mutated at 
advanced HCC  stages compared to earlier ones (Oda, Tsuda, Sakamoto, & Hirohashi, 
1994; Qin et al., 2002). The p16 (CDKN2A) tumor suppressor gene is known to be 
involved in the cell cycle regulation, and was shown to be suppressed in HCC due to 
its hypermethylation. Mainly, p16 suppression occurs more frequently in advanced 
HCCs (40%) than in early HCC cases(A. Hui et al., 1996). Other HCC-associated 
deregulated oncogenes and tumor suppressors include β-catenin, CTNNB1, ARID2, 
ARID1A, MLL, ErbB family members and E-cadherin (Farazi & DePinho, 2006; 
Fujimoto et al., 2012).  
Deregulation of several signal transduction pathways also contributes to the 
development of HCC. Among these signalling pathways is the Wnt/β-catenin, 
RaslMAPK/EGFR,IGF and AKT/PKB(Guichard et al., 2012; Wong & Ng, 2008). 
All of the above mentioned molecular alterations are more frequent in advanced 
stages of HCC than in early stages. Thus, currently, the research is directed towards 
identifying new molecular markers associated with early stages of HCC. Among these 
are the heat-shock 70 (hsp70) and adenylate cyclase-associated protein 2(CAP2). In 
fact, both these genes were found to be detected in early HCC stages in addition to their 
high expression in advanced stages(Chuma et al., 2003; Shibata et al., 2006). 
Other molecular markers detected in the blood are used for HCC diagnosis. Αlpha-
fetoprotein (AFP) is the most commonly used HCC tumour marker (Debruyne & 
Delanghe, 2008). Among its three forms (AFP-L1,AFP-L2 and AFP-L3), AFP-L3 has 
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the highest sensitivity and specificity percentages in HCC detection (96.9%, 92% 
respectively) (Hiraoka et al., 2015). In addition to AFP, Glypican-3 (GPC3), 
Transforming growth factor-β1 (TGF-β1), Hepatoma-associated gene (HTA), AFP 
mRNA and miRNAs were also described as crucial blood diagnostic markers of HCC. 
(Liu et al., 2010; Lun, Ai-Qin, & Xuan, 2014; Zhi, Zhan, Deng, & Huang, 2007). 
1.2. Cofactor of BRCA1 
1.2.1 Identification, Structure and Function 
Cofactor of BRCA1 (COBRA1) was first isolated from a human ovary cDNA 
library and identified as a novel interacting protein with the breast cancer susceptibility 
gene (BRCA1)(Ye et al., 2001). Previous studies have identified the role of BRCA1 in 
regulating several nuclear processes such as transcription, recombination and DNA 
repair (Chapman & Verma, 1996) (Lee, Collins, Brown, Lee, & Chung, 2000). These 
nuclear functions are believed to be mediated by the chromatin de-condensation 
activity of BRCA1, which occurs in the two BRCT domains required for interacting 
with several transcription-regulatory factors such as p53, RNA helicase A and 
CBP/p300 (Ye et al., 2001; Zhong et al., 2004). 
In a study aiming to identify cofactors recruited by BRCA1 to mediate chromatin 
de-condensation, a novel cofactor of BRCA1 (COBRA1) was identified and found to 
be bound to the first chromatin de-condensation domain (BRCT) of BRCA1 (Ye et al., 
2001). The results of the study revealed that BRCA1-mediated chromatin de-
condensation is partially dependent on its recruitment of COBRA1. Remarkably, 
COBRA1 was found to have a sufficient ability to induce a large scale of chromatin 
de-condensation by itself. Moreover, BRCA1 mutations involved in the enhancement 
of chromatin de-condensation were found to increase the affinity and recruitment of 
BRCA1 to COBRA1 (Ye et al., 2001). These results indicated that chromatin 
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remodelling is a significant step in both BRCA1 and COBRA1-mediated nuclear 
activities. 
COBRA1 encodes a 580-amino acid protein, in which 17% of its constituents are 
rich in leucine residues(Ye et al., 2001). It contains three repeats of the LXXLL motif. 
In fact, this motif is a main part of many transcription coactivators, due to its ability of 
mediating the ligand-dependant interactions with several steroid hormone receptors 
(Heery, Kalkhoven, Hoare, & Parker, 1997; Ye et al., 2001). 
In 2003, COBRA1 was found to represent the β-subunit of the negative transcription 
elongation factor complex (NELF), a 4-subunit complex that is known by its ability to 
induce the stalling of RNA polymerase II during the early phase of transcription 
elongation. The NELF complex is reported to regulate many genes known to be 
involved in cellular mechanisms such as the cell cycle, differentiation, proliferation and 
metabolism (Yamaguchi et al., 1999). The role of COBRA1 in early embryogenesis 
was identified later through in vivo studies, where it was found that knocking out 
COBRA1 in the mouse leads to early embryonic lethality (Amleh et al., 2009). 
Having no DNA binding domain, COBRA1 could repress the transcription of its 
target genes through interacting with other DNA-binding transcription factors such as 
the remaining members of the NELF complex, AP1 complex, ERα as well as the 
androgen receptor (AR)(S. E. Aiyar et al., 2004; J. Sun, Blair, Aiyar, & Li, 2007; Zhong 
et al., 2004). This ability of COBRA1 to interact with different transcription complexes, 
suggests its involvement in regulating different cellular processes including 
transcription, gene expression and tumorigenesis. Below is an overview of some of the 
main roles of COBRA1 in transcription regulation and tumorigenesis. 
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1.2.2 COBRA1 role in transcription regulation 
The transcription process (controlled by RNA polymerase II) is a crucial step by 
which several genes and biological processes are controlled (Narita et al., 2003). 
During the elongation phase, shortly after the transcription initiation, RNAPII escapes 
from the promoter-proximal region and pauses 20-45 nucleotides downstream the 
transcription start site, influencing by this, the efficiency of transcription and hindering 
the transition to the productive elongation phase. This process is known as ‘promoter 
proximal pausing or RNAPII stalling’, and was found to be associated with a wide 
variety of biological systems (Adelman & Lis, 2012; Gilchrist et al., 2008; Narita et 
al., 2003). The regulation of RNA stalling requires the involvement of negative and 
positive transcription elongation factors.  
DRB (5,6-dichloro-1-β-D-ribofuranosylbenzimidazole) sensitivity-inducing factor 
(DSIF) is a heterodimeric complex composed of p14 and p16. Along with the NELF 
complex, it is responsible for the transcriptional pausing process (Narita et al., 2003; 
Wada et al., 1998). Previous studies have revealed that DSFI doesn’t have an effect on 
the catalytic activity of RNAPII upon binding to it (Yamaguchi et al., 1999). Similarly, 
NELF doesn’t have a binding affinity to either DSIF or RNAPII alone. Instead, the 
DSIF/RNAPII complex is required for such binding to occur. This association is 
believed to activate the transcriptional pausing process(Yamaguchi, Inukai, Narita, 
Wada, & Handa, 2002). 
P-TEFB, a protein kinase composed of Cdk9 and one of the cyclin complexes T1, 
T2a, T2b and K, is believed to reverse the transcription elongation inhibition by 
preventing the action of both DSIF and NELF(Price, 2000; Yamaguchi et al., 1999). It 
is believed that the kinase activity of P-TEFB is crucial for stimulating the 
transcriptional elongation. Through phosphorylating the C-terminal domains of 
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RNAPII (CTD), release of both DSIF and NELF from RNAPII is likely to occur. As a 
result, the binding of 3’ elongation factors is facilitated, resulting in stimulation of the 
elongation process (Bourgeois, Kim, Churcher, West, & Karn, 2002; Ping & Rana, 
2001; Price, 2000). 
Despite the involvement of the RNAPII stalling process in a variety of biological 
mechanisms, at first, only few genes were reported to be regulated by this process such 
as the mammalian proto-oncogene junB, Drosophila Hsp70, and HIV RNA(Wu et al., 
2005). The fact that only few genes were associated with the RNA stalling process has 
led many to view it as a rare phenomenon. However, a genome-wide analysis of 
Drosophila genes has changed this view by identifying more than 18000 Drosophila 
genes associated with RNA stalling in their promoter regions(Muse et al., 2007; 
Zeitlinger et al., 2007). Similarly, a study of RNAPII distribution in human cells has 
identified the importance of the RNA stalling step in regulating the expression of many 
genes known to have a role in the development (Guenther, Levine, Boyer, Jaenisch, & 
Young, 2007; Muse et al., 2007; Zeitlinger et al., 2007).  
All of these studies have increased the interest into understanding and identifying 
the mechanisms by which the RNAPII stalling process is regulated. In a microarray 
analysis of NELF regulated genes in drosophila, NELF was found to affect the 
expression of many genes involved in a variety of cellular processes (Gilchrist et al., 
2008). Unexpectedly, most of the target genes have shown reduced levels upon NELF 
knockdown, suggesting a role of NELF-dependent RNA stalling in enhancing the gene 
expression in addition to suppressing it. This observation was explained by the ability 
of the RNA stalling process of sustaining the chromatin architecture at the promoters 
regions of these genes (Gilchrist et al., 2008). 
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1.2.3 COBRA1 interaction with other transcription factors 
Having no DNA binding domain, COBRA1 could repress the transcription of its 
target genes through interacting with other DNA-binding transcription factors such as 
the remaining members of the NELF complex, the Estrogen receptor α (ERα), the 
Androgen receptor (AR) as well as the activator protein-1 (AP-1) complex (S. E. Aiyar 
et al., 2004; J. Sun et al., 2007; Zhong et al., 2004). 
 In 2003, COBRA1 was found to represent the β-subunit of the negative 
transcription elongation factor complex (NELF)(Narita et al., 2003). The negative 
elongation factor (NELF) is a transcription regulatory complex that was identified by 
its ability to induce stalling of RNA polymerase II (RNAPII) with the assistance of the 
DRB sensitivity-inducing factor (DSIF) during the early phase of transcription 
elongation (Yamaguchi et al., 1999). 
The NELF complex consists of four subunits; NELF-A (66kDa), NELF-B (62kDa) 
NELF-C/D (60kDa) and NELF-E (46kDa). NELF-A gene (WHSC2), which was 
identified as a potential participant in the Wolf-Hirschhorn syndrome, contains an RNA 
polymerase II binding domain, through which the NELF complex binds to RNA 
polymerase II. NELF E, which has an RNA recognition domain, is responsible for 
binding to the emerging RNAs arising from polymerase II. NELF-C/D, which are 
homologous to the TH1-like mammalian protein, are believed to arise from a common 
mRNA through alternative usage of translation initiation codons. Hence, either a C or 
a D subunit is present in the NELF complex (Gilchrist et al., 2008; Narita et al., 2003). 
Along with the NELF B subunit (COBRA1), all of these subunits are required for 
the assembly of a functional NELF complex. In fact, several studies have identified the 
interdependent manner by which the NELF subunits are regulated, where it was 
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reported that a depletion in one of these subunits results in a similar effect on the 
remaining subunits (Narita et al., 2003; J. Sun et al., 2008). 
Both Estrogen receptor α (ERα) and androgen receptor (AR) are DNA-binding 
transcription factors that belong to the steroid hormone receptor family. These factors 
are believed to control the transcription of genes by either a ligand-dependent or 
independent means (Nilsson et al., 2001). The strength of such a transcription process 
is highly influenced by the availability of cognate hormones in addition to the 
recruitment of several transcription co-regulators (Glass & Rosenfeld, 2000; Shang, 
Hu, DiRenzo, Lazar, & Brown, 2000). Most of which are believed to influence the rate 
of transcription by modifying the chromatin structure as well as facilitating the 
hormone receptors communication with the transcription machinery(Glass & 
Rosenfeld, 2000; McKenna & O'Malley, 2002). 
 In addition to these regulatory processes, transcription elongation and RNA 
processing are also linked with gene expression control (Auboeuf et al., 2004; 
Orphanides & Reinberg, 2000; Zorio & Bentley, 2001). Previous in vivo studies have 
indicated a novel role of COBRA1 as a corepressor of the ER-α dependent gene 
expression through stalling of RNAPII (S. E. Aiyar et al., 2004). Upon Estrogen 
stimulation, COBRA1 along with the other NELF subunits binds to ERα in breast 
cancer cells and is recruited to the promoters of ER target genes, resulting in RNAPII 
stalling and suppression of the ERα-mediated transcription(S. E. Aiyar et al., 2004). 
This regulation of the transcription has introduced a unique level of hormonal gene 
regulation which is diverse from most of the known steroid receptors co-regulators 
actions(J. Sun et al., 2007). 
The majority of nuclear receptors (NR) co-regulators have the ability of binding to 
several receptors as well as mediating the regulation of transcription. This capability is 
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mainly explained by the presence of many NR-binding motifs ‘LXXLL’ within their 
structures(Heinlein & Chang, 2002; McKenna & O'Malley, 2002). Having this 
structural feature, COBRA1 was found to bind to several steroid hormone receptors 
with diverse affinity degrees. In fact, COBRA1 was found to bind to the androgen 
receptor (AR), progesterone receptor B (PRB) and glucocorticoid receptor (GR). 
Among these three nuclear receptors, AR was reported to have the strongest binding 
affinity to COBRA1. In fact, through its binding to the ligand binding domain (LBD) 
of AR, COBRA1 was found to regulate the AR-dependent transcriptional processes.  
In addition to binding to the NELF subunits and steroid hormone receptors, 
COBRA1 was also found to interact with the transcription factor activator protein 
1(AP-1), a heterodimer composed of c-Fos and c-Jun family proteins (Hess, Angel, & 
Schorpp-Kistner, 2004). The role of COBRA1 in regulating the AP-1 transcriptional 
activity was investigated by Zhong et al in 2004, where it was proved for the first time 
that overexpressing COBRA1 represses the activator protein 1(AP1) transcriptional 
activity. On the other hand, reduction of COBRA1 via siRNA enhances the AP-1 
transcriptional activity. This action of COBRA1 was attributed by its ability to bind to 
both c-Fos and c-Jun family members. Particularly, the interaction with the c-Fos 
members is essential for this inhibitory action, where the lack of the c-Fos binding site 
in COBRA1 completely stops the inhibitory effect of COBRA1 on the AP1-mediated 
transcriptional activity (Zhong et al., 2004). Given that AP-1 is known to be involved 
in many biological processes including cell fate and oncogenesis, COBRA1 was 
proposed to have a function in regulating these processes through AP-1 signalling.   
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1.2.4 Role in Cancer 
The role of COBRA1 in cancer was first driven by its identification as a BRCA1-
interacting nuclear protein, and its potential role in regulating nuclear events such as 
transcription, cell cycle, DNA repair and cell proliferation(Zhu et al., 2004). In 
addition, the role of COBRA1 in regulating the AP1- mediated transcriptional activity 
and ligand-dependant gene expression, which are both involved in cancer development, 
has raised the possibility of its involvement in cancer (S. E. Aiyar et al., 2004; J. Sun 
et al., 2007; Zhong et al., 2004).  
To date, COBRA1 role in the tumorigenesis of breast and gastrointestinal carcinoma 
has been investigated and identified. In breast cancer, previous studies have identified 
COBRA1 as a tumor suppressor. Upon the identification of its ability to interact with 
BRCA1 in 2001, the mRNA and protein levels of COBRA1 were found to be reduced 
in different breast cancer cell lines (Zhu et al., 2004). In addition, a physical interaction 
between BRCA1 and COBRA1 was observed in these cells, indicating its possible 
involvement in the regulation of breast cancer growth (Zhu et al., 2004). Moreover, 
COBRA1 was found to physically bind to the ligand binding domain (LBD) of ERα 
and inhibits the estrogen-dependent transcription in breast cancer cells (S. E. Aiyar et 
al., 2004).  
In line with the effect of COBRA1 in the regulation of breast cancer growth, another 
study done by Sun et al., (2008) has demonstrated a tumor-suppression role of 
COBRA1 in breast cancer. In this study, it was found that COBRA1 expression is 
significantly reduced in metastatic breast cancer samples (J. Sun et al., 2008). These 
observations go in line with another study that revealed that COBRA1 can regulate the 
expression of genes associated with breast cancer progression and metastasis such as 
the trefoil factor1 gene (TFF1) (S. E. Aiyar et al., 2004; Smid et al., 2006). 
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Contrasting its role in breast cancer, COBRA1 was found to act as an oncogene in 
the upper gastrointestinal carcinomas (UGCs). In fact, COBRA1 was found to be 
overexpressed in 60% of primary UGG samples compared to normal samples 
(McChesney et al., 2006). Unlike breast cancer, COBRA1 overexpression was 
accompanied by down regulation of TFFI (McChesney et al., 2006). This contradictory 
role of COBRA in breast and gastrointestinal carcinoma is believed to be due to its 
interaction with different site-specific transcription factors. Thus, regulating distinct 
transcription processes in different cell and tissue types (Adams et al., 2005; 
McChesney et al., 2006; J. Sun et al., 2008). 
The role of COBRA1 in other cancer types has not been identified yet. However, 
it’s worth mentioning that a previous tissue array study has indicated a significant 
expression of COBRA1 in the epithelial of many tissues, indicating the possibility of 
its involvement in the tumerogenousis in tissues other than breast and upper 
gastrointestinal tract (J. Sun et al., 2008). Given the role of COBRA1 in influencing the 
alternative splicing pattern of receptor genes, current research is directed towards 
identifying cancer-associated alternative splicing patterns of COBRA1-regulated 
genes. Moreover, due to its role as a modulator of androgen-dependent transcription in 
addition to the importance of androgen in the development of prostate cancer, 
COBRA1 was suggested to have a role in the tumorigenesis of prostate cancer. 
However, further studies to confirm these notions are required.  
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 1.2.5 Role in Hepatocellular Carcinoma  
In hepatocellular carcinoma, Previous studies have revealed a potential role for 
COBRA1 in HCC pathogenesis (Youssef, Shawer, Afify, & Amleh, 2016). In addition, 
other studies have established a possible link between COBRA1 and several proteins 
known to be involved in tumorigenesis and anti-apoptotic pathways (El Zeneini et al., 
2016). In this study, COBRA1 was knocked-down. As a result, the growth and 
migration of HCC cells were significantly decreased. In addition, a decrease in the 
expression of the proliferation marker; Ki-67 as well as the anti-apoptotic gene; 
survivin was also observed (El Zeneini et al., 2016). 
HYPOTHESIS AND SPECIIC OBJECTIVES 
The above-mentioned data obtained from ongoing research suggests strongly a positive 
role of COBRA1 in the migratory and proliferation potentials of HCC. Therefore, we 
hypothesize that COBRA1 overexpression will have a role in both the proliferation and 
migration potentials of HCC cells. To address this hypothesis, our study had the 
following three objectives: 
1. To establish a successful COBRA1-overexpression in the HCC cell line, HepG2. 
HepG2 represents a pure cell line of Hepatocellular Carcinoma. It is derived from 
a 15-year old Caucasian, American male with early stage HCC (Costantini, Di 
Bernardo, Cammarota, Castello, & Colonna, 2013; Fornari et al., 2010; Yie et al., 
2015). 
2. To examine the levels of the NELF complex subunits as well as the NELF complex-
regulated genes, TFF1 and TFF3 following COBRA1 overexpression. 
3. To investigate the effect of COBRA1 overexpression on the proliferation and 
migration of HepG2 cells as well as the expression of tumorigenesis-related genes. 
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CHAPTER 2. MATERIALS AND METHODS 
 
2.1. Cell Culture 
The human hepatocellular carcinoma cell line, HepG2, was kindly provided by Dr. 
Mehmet Ozturk from the Department of Molecular Biology and Genetics, Bilkent 
University, Turkey. The cells were cultured in RPMI 1640 (Lonza, USA) supplemented 
with 10% heat-inactivated fetal bovine serum (Invitrogen, USA) and 5% Penicillin-
streptomycin antibiotic (Invitrogen, USA). Cells were incubated at 37°C in a 
humidified atmosphere of 5% CO2 and used when in the log phase of growth. Cells 
were regularly observed by the inverted microscope (Olympus IX70, USA) for their 
morphology, growth, lack of any biological contamination and the percentage of 
confluence. 
2.2. Viable Cell Count 
The cells viability was estimated using the trypan blue dye-exclusion method, where 
an aliquot of the cells was two-fold diluted using 0.4% w/v trypan blue. 10 ul of the 
diluted cell suspension was loaded into the haemocytometer’s chamber. The number 
of cells in the chamber’s four outer squares was then counted. To determine the cell 
count, the following formula was applied:  
[Viable cell count (live cells/ml) = (Number of live counted cells x dilution factor x 
10,000) / Total number of counted squares]. 
2.3. Plasmid constructs 
2.3.1 pCMV5-HCOBRA1Plasmid 
The pCMV5-HCOBRA1 expression plasmid was generously provided by Dr.Rong 
Li, University of Texas Health Science Centre, San Antonio-USA. To generate 
pCMV5-HCOBRA-1, EcoRI and SalI enzymes were used to clone the 5`UTR+CDS of 
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HCOBRA1+flag to the 4.7 Kb sized pCMV5 vector, resulting in a plasmid of the size 
of 6.6 Kb. The plasmid was shipped on a filter paper and recovered by immersing in 
TE buffer followed by transforming into Top10 competent bacterial cells. 
2.3.2 pCMV5-empty plasmid 
In order to be used as a negative control in the transfection process, an empty 
pCMV5-plasmid was prepared. Briefly, pCMV5-HCOBRA1 was digested with EcoRI 
and SalI enzymes. The empty vector (4.7 fragment) was purified using QIAquick Gel 
Extraction Kit. The 5` overhangs resulted from the digestion were blunted by filling in 
with the Klenow fragment of DNA polymerase I. One unit of klenow was added per 1 
µg of DNA, followed by incubation at 25°C for 15 minutes and heating at 67 °C for 20 
minutes. The blunted vector was then re-ligated using T4 DNA ligase. Correct ligation 
was confirmed by restriction linearization using BamH1 enzyme as well as the colony 
PCR technique. The ligation reaction was then transformed into Top10 competent cells, 
and glycerol stocks of the vector were prepared. 
2.3.3 pEGFP-N1 Plasmid 
The pEGFP-N1expression plasmid was provided by Dr. Ahmed Osman, Ain Shams 
University, Egypt. The expression vector was originally purchased from Clontech 
(http://www.clontech.com). 
2.4. Transformation 
In order to have larger amounts of plasmid DNA for further experiments, bacterial 
cells were transformed with the acquired plasmids and propagated in bacterial medium 
prior to preparation of glycerol stocks and harvesting for DNA. 
Top10 competent cells were transformed with the suitable plasmids. 50 µl of the 
cells were first thawed on wet-ice. 1-5 µl of the plasmid-DNA were added to the 
competent cells and mixed gently. The mixture was left on ice for 30 minutes followed 
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by an immediate heat-shock at a temperature of 42 ºC for 30 seconds. Following this, 
900 µl of pre-warmed LB media were added to the mixture. The vial containing the 
cells was then incubated at 37 ºC for 1 hour. 50 µl of the transformation mixture were 
plated on LB agar plates that contain 100 µg/ µl ampicillin. The plates were then 
incubated at 37 ºC overnight. A single colony was selected the next day and placed in 
a culture containing 5 ml of LB media with 100 µg/µl ampicillin. Following an 
overnight incubation in a 37 ºC shaker, the cells were harvested and the plasmid DNA 
was extracted using Mini Prep Kit (Qiagen). 
To prepare glycerol stocks, 600 µl of the liquid culture were added to 400 µl of 50% 
glycerol and stored at -80 ºC for further use. 
2.5. Restriction digestion 
Restriction enzymes were used to confirm the identities of the newly obtained 
plasmids. EcoR1 and SalI restriction enzymes were used to digest the pCMV5-
HCOBRA1 vector. EcoRI was used to linearize the pCMV5-COBRA1 and the 
pEGFP.N1vectors. SalI was used to linearize the pEGFP.N1vector. BamH1was used 
to linearize the pCMV5-empty vector. The digestion reaction was performed in a final 
volume of 20 µl, consisting of 15 µl distilled water, 2 µl of 10 X NEBuffer 3.1to a final 
concentration of 1X, 0.25 µg of the extracted plasmid DNA and 1 µl of each enzyme. 
The linearization reaction was performed in a final volume of 20 µl, consisting of 15 
µl distilled water, 2 µl of 10X NEBuffer EcoRI or 10 X NEBuffer 3.1 to a final 
concentration of 1X, 0.25 µg of the extracted plasmid DNA and 1.8 µl of EcoRI, SalI 
or BamH1 enzyme. The reaction was gently mixed and incubated for 1 hour at 37 ºC. 
The undigested plasmids, linearized plasmids and digested plasmids were run on a 1% 
agarose gel and visualized using Gel Doc EZ System (Bio-Rad, USA). 
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As EcoRI cuts the pCMV5-HCOBRA1 plasmid once at the 0.92 Kb position, a 
6.557 Kb fragment will be expected. As SalI enzyme cuts the plasmid once at the 0.968 
position, when used together with EcoRI, two bands of the sizes 4.609 Kb and 1.9 Kb 
will be expected on the agarose gel. As BamH1 cuts the plasmid once at the 0.98 Kb 
position, a 4.657 Kb fragment will be expected. As EcoRI cuts the pEGFP.N1 plasmid 
once at the 0.629 Kb position, a 4.733Kb fragment will be expected. As SalI enzyme 
cuts the plasmid at 0.639 Kb position, a 4.733 Kb fragment will be expected. 
2.6. Colony PCR 
The identity of the pCMV5-HCOBRA1 and pCMV5-empty vector was further 
confirmed by the colony PCR technique. A single colony obtained following an 
overnight culture of pCMV5-HCOBRA1 and/or pCMV5-empty transformed bacterial 
cells was suspended in 20 µl distilled water and boiled at 95 ºC. The PCR reaction for 
colony analysis was prepared in a final volume of 25 μl  consisting of the followings: 
2.5 µl of 10X DreamTaq Green Buffer(Thermo Scientific), 0.5 μl dNTPs mix (Thermo 
Scientific), 0.2 μl Dream Taq DNA Polymerase (Thermo Scientific), 1 μl of forward 
and reverse specific primers, 1 μl  of the colony suspension as well as H2O. The PCR 
conditions were as follows: initial denaturation at 95ºC for 4 minutes, followed by 32 
cycles of (denaturation at 95ºC for 30 seconds, annealing at 59.5ºC for 30 seconds and 
extension at 72ºC for 45 seconds) before finishing with a final extension at 72ºC for 7 
minutes. The amplified PCR products were run on a 1.5% agarose gel and visualized 
using Gel Doc EZ System (Bio-Rad, USA). 
2.7. Cell transfection  
Transient transfection of HepG2 cells with pCMV5-HCOBRA1 was performed 
using the lipofectamine 3000 reagent (Life Technologies) according to the 
manufacturer’s protocol. Briefly, HepG2 cells were seeded in six-well culture plates, 
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and incubated for 24 hours until reached 70-90% confluence. Before transfection, 3.75 
µl of lipofectamine 3000 were added to 125 µl of Opti-MEM reduced serum medium, 
and incubated for 5 minutes at room temperature. Meanwhile, 2.5 µg pCMV5-
HCOBRA1 was diluted in 125 Opti-MEM reduced serum medium and 5 µl of P3000 
reagent. Following this, the two dilutions were mixed and incubated for 20 minutes to 
allow formation of the complex. The DNA-lipofectamine complexes (250 µl) were then 
added to each well of the 6-well plate. Media was changed 8 hours post transfection. 
48 hours following transfection, cells were harvested for RNA and protein analysis.  
As controls, cells were either left un-transfected (blank) or transfected with an empty 
vector (pCMV5-empty vector). The pEGFP.N1 vector was used as a positive control 
to determine the transfection efficiency. Forty eight hours following transfection, the 
florescent cells were visualized by the Olympus IX70 fluorescence microscope using 
the GFP filter set. Likewise, the total number of cells in the same field were visualized 
using the bright filter set. Photo-microscopy was done using cellsens imaging software 
(Olympus IX70). Cell counts were performed using ImageJ Software (National 
Institute of Health, USA, http://www.imagej.nih.gov/ij). The transfection efficiency 
was then estimated according to the following formula: 
Tansfection efficiency = (florescent cells per field /total number of cells per field) 
X 100’ 
2.8. RNA Extraction 
Total RNA was extracted from HepG2 cells using Trizol reagent (Invitrogen, USA) 
according to the manufacturer's instructions. The extracted RNA was suspended in 
diethlpyrocarbonate –treated (DEPC) water. Following this, the concentration of the 
extracted RNA was measured at 260 nm using an UV spectrophotometer (Shimadzu, 
Japan). 
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2.9. Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Total RNA (0.5 μg) was reverse transcribed using a Revert Aid First strand cDNA 
synthesis Kit (Thermo Scientific, USA). Messenger RNA expressions were determined 
using semi-quantitative RT-PCR. The PCR reaction was prepared by mixing the 
following reagents: 10X DreamTaq Green Buffer (Thermo Scientific), 10 mmol/L 
dNTPs mix) (Thermo Scientific), 1X Dream Taq DNA polymerase (Thermo 
Scientific), forward and reverse specific primers and water. β-actin was used as an 
internal control. The primers used for the amplification of the genes are listed in Table 
(1).  PCR amplifications conditions were programmed for 5 minutes at 95°C, followed 
by cycles of (denaturation at 95ºC for 30 seconds, annealing at 56ºC-63ºC depending 
on the used primers for 30 seconds, extension at 72ºC for 45 seconds) and finishing 
with 7 minutes at 72ºC. The amplification process was carried out for a number of 
cycles depending on the used primers (Table 1). The PCR products were then separated 
on a 1.5% agarose gel and visualized using Gel Doc EZ System (Bio-Rad, USA). 
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Table 1. RT-PCR primer sequences, annealing temperatures, cycle numbers and 
amplicon sizes (F: forward primer, R: reverse primer, bp: base pair) 
  
Gene Primer Sequence 
Annealing 
Temp. 
Cycle 
number 
Amplicon  
size (bp) 
B-ACTIN 
F: GCAAAGACCTGTACGCCAAC 
R: GAGACCAAAAGCCTTCATACATCTC 
58°C 27 cycles 777 
COBRA1 
F: ACATCACCAAGCAGAGGAA 
R: GATCCAGCTGTTCCAGCTTC 
59.5°C 
32 cycles 
 
366 
Survivin 
F: TTGAATCGCGGGACCCGTTGG 
R: CAGAGGCCTCAATCCATGGCA 
61˚C 32 cycles 
Isoform 1: 477 
Isoform 2: 359 
Isoform 3: 546 
NELF-A 
F: GTCGGCAGTGAAGCTCAAGT 
R: TTCACACTCACCCACCTTTTCT 
60˚C 35 cycles 250 
NELF-
C/D 
F: GAAGAAGGAGAGACCCCAGC 
R: GTGCCCAAGGCTAGTGTGAT 
56˚C 28 cycles 443 
NELF-E 
F: TGGTGAAGTCAGGAGCCATCAG 
R: CGCCGTTCAGGGAATGAATC 
63˚C 28 cycles 565 
Ki-67 
F: CTTTGGGTGCGACTTGACG 
R: GTCGACCCCGCTCCTTTT 
60˚C 28 cycles 199 
TFF1 
F: TTTGGAGCAGAGAGGAGGCAATGG 
R: TGGTATTAGGATAGAAGCACCAGGG 
60˚C 32 cycles 240 
TFF3 
F: GTGCCAGCCAAGGACAG 
R: CGTTAAGACATCAGGCTCCAG 
58˚C 35 cycles 302 
 
2.10. Western blot Analysis 
Total cell lysates were prepared using ice-cold PBS and laemmli lysis buffer 
supplemented with 1X Halt Protease Inhibitor Cocktail (Thermo Scientific, USA). The 
concentrations of proteins were determined using Thermo Scientific Pierce BCA 
protein kit (Pierce Biotechnology, USA) according to the manufacturer’s protocol. 
Equivalent amounts (20-50 μg) of proteins diluted in a lysis buffer were mixed with 
the loading dye and separated on a 12 % SDS-PAGE. Consequently, they were blotted to a 
nitrocellulose membrane. Following blocking with 5% non-fat dry milk in 1X PBST 
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(0.01% Tween-20 in PBS) at room temperature for 1 hour, the membrane was 
incubated with the primary antibody at 4 ºC overnight. Following three times washing (5 
minutes each) with the wash solution (1 X PBS and 0.1% Tween), the membrane was 
incubated with alkaline phosphatase conjugated secondary antibody (either goat anti-
rabbit IgG (KPL) or goat anti-mouse (KPL) diluted as 1:20,000 in 5% non-fat milk) at 
RT for two hours, and washed 3 times with the wash solution. For detection, the membrane 
was incubated with the chemiluminescent PhosphoGLO Substrate (55-60-04, KPL) 
for 5 minutes prior to exposing it to an X-ray film in the dark. Signals were then 
detected by developing the film in developer and fixer solutions. Anti-β-tubulin 
(Sigma, T7816) (1:20,000 in 5% non-fat dry milk), anti-COBRA1 (Abcam, ab167401) 
(1:1000 in 5% non-fat dry milk) and anti-NELF-E (Abcam ab170104) (1:1000 in 5% 
non-fat dry milk) were used as primary antibodies in this study.  
In order to use the same membrane for detection of other proteins, the membranes 
were incubated in the stripping buffer (0.5 M Tris-HCl,10% SDS and beta-
mercaptoethanol) at 55 °C for 30 minute prior to excessive washing with water to 
remove any beta-mercaptoethanol traces. The membranes were then blocked with 5% 
non-fat dry milk in 1X PBST before incubating with another primary antibody. 
2.11. Wound-healing assay  
The wound-healing assay was used to evaluate the migratory potentials of HepG2 
cells. Forty-eight hours post transfection, the cells monolayer was scraped by a yellow 
pipette-tip creating a cross-shaped wound. The cells were then washed with PBS to 
remove any detached cells and incubated for 24 hours. Images of the same wound 
location were obtained at both the (0 hr) and the (24 hr) times. The open wound area 
was analysed using the TScratch software (Gebäck, Schulz, Koumoutsakos, & 
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Detmar, 2009), and the percentage wound closure was calculated according to the 
formula: 
Percentage wound closure = [(wound area 0 hr-wound area 24 hr)/ wound area 0hr] x 
100 
 2.12. Statistical analysis 
For PCR and Western blot analysis, the bands intensities were quantified and 
normalized per the used internal control using Image J software (National Institute of 
Health, USA, http://www.imagej.nih.gov/ij). Relative differences in gene expression 
are described as fold change to the empty vector-transfected cells. 
All statistical analysis were performed using GraphPad Prism 7.0 (GraphPad, San 
Diego California USA, http://www.graphpad.com/). All the data represent the average 
± standard deviation (SD) from three independent experiments. When comparison was 
made between two different groups, statistical significance was determined using an 
unpaired student's t-test (two-tailed). One-way ANOVA (Analysis of Variance), 
followed by a Bonferroni post-test was used to determine the statistical significance 
among multiple different experimental groups. In all analyses, P < 0.05 was considered 
statistically significant (* p <0.05; ** p value <0.01; *** p value <0.001). 
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CHAPTER 3. RESULTS 
 
3.1. Confirmation of plasmids identities 
Before using the plasmids in the transfection assays, their identities were confirmed 
by performing restriction digests on the plasmids and comparing the obtained 
fragments sizes with those expected from the corresponding plasmid restriction map. 
The pcMV5-HCOBRA1 plasmid restriction digestion by both EcoRI and SalI resulted 
in two bands of the sizes 4.609 and 1.9 Kb as expected from the restriction map. EcoRI 
digestion resulted in a linearized plasmid with the expected band size of 6.6 Kb (Figure 
1A). The pCMV5-empty plasmid restriction digestion by BamH1 resulted in a 
linearized plasmid with the expected band size of 4.657 Kb (Figure 1B). The 
pEGFP.N1 plasmid restriction digestion by EcoRI resulted in a linearized plasmid with 
the expected band size of 4.7 Kb. As such, pEGFP.N1 plasmid restriction digestion by 
SalI resulted in a linearized plasmid with the expected band size of 4.7 Kb (Figure 1C). 
The pCMV5-HCOBRA1 and the pCMV5-empty plasmids identities were further 
confirmed through colony PCR. Amplification of the colony obtained from the 
pCMV5-HCOBRA1 transformed cells resulted in an amplicon of the expected size of 
366 bp. On the other hand, amplification of the colony obtained from pCMV5-empty 
plasmid resulted in no bands (Figure 1D). 
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Figure 1. Confirmation of plasmids identities 
Lane 1 shows GeneRuler 1 Kb ladder (A) pCMV5-HCOBRA1 restriction digests: Lane 2 shows the 
uncut plasmid. Lane 3 shows an EcoRI digestion resulting in a band of the approximate size of 6.6 Kb.  
Lane 4 shows EcoRI & Sall digestion resulting in two bands of the sizes of 4.609 and 1.9 Kb. (B) The 
pCMV5-empty plasmid restriction digests: Lane 2 shows the uncut plasmid. Lane 3 shows BamH1 
digestion resulting in a band of the size of 4.657 Kb. (C) pEGFP-N1 restriction digests: Lane 2 shows 
the uncut plasmid. Lane 3 shows EcoRI digestion resulting a band of the size of 4.7 Kb. Lane 4 shows 
SalI digestion resulting in a band of the size of 4.7 Kb. (D) Colony PCR: colonies obtained from pCMV5-
HCOBRA1 transformed cells resulted in a 366 bp amplicon (Lane 2). Colonies obtained from pCMV5-
empty plasmid resulted in no bands.  
 
3.2. Optimal protocol for HepG2 cells transfection 
To determine if lipofectamine 3000 is effective in overexpressing of COBRA1 in 
HepG2 cells, we first optimized the best protocol to be used in transfecting HepG2 
cells. A series of optimizations were conducted per the manufacturer’s 
recommendations. We first compared the transfection efficiency between both the 
reverse and forward transfections. Then, we attempted to determine the most suitable 
lipofectamine volume to be used in the transfection. Finally, we examined whether 
increasing the incubation time of the cells following transfection can further enhance 
the transfection efficiency. 
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3.2.1. Reverse transfection versus Forward transfection 
Both reverse and forward transfections were used to overexpress COBRA1 in 
HepG2 cells. Usually, when using the forward transfection, cells are seeded 24 hours 
prior to transfection. On the other hand, in the reverse transfection, the cells are added 
directly to the transfection mix(Erfle et al., 2007).  
Overexpression efficiency was compared between both reverse and forward 
transfections based on the percentage of the green florescent (pEGFP.N1+) cells. As 
shown in figure 2 A, the forward transfection resulted in a higher efficiency (45%) than 
that observed with the reverse transfection (20%). Accordingly, the forward 
transfection was used in the subsequent transfection experiments. 
3.2.2. Lipofectamine volume  
Two lipofectamine volumes (3.75 μL and 7.5 μL) were used to form lipofectamine-
DNA complexes as recommended by the supplier. Transfection using 3.75 μL 
lipofectamine resulted in a transfection efficiency of 45 %. On the other hand, 
transfection using 7.5 μL lipofectamine resulted in a transfection efficiency of 30%. 
Using this volume, detrimental cytotoxicity was observed following the transfection 
when compared to un-transfected cells (Figure 2 B). 
Beside the GFP expression, COBRA1 overexpression was also compared between 
the two tested volumes. As shown in figure 2 C&E, cells transfected with 3.75 μL of 
lipofectamine showed the highest overexpression on both the mRNA steady state 
expression and protein levels. Due to its higher transfection efficiency as well as low 
cytotoxic effects, the 3.75 μL lipofectamine was used in the subsequent transfections. 
3.2.3. Incubation duration 
We further optimized our protocol by examining the effect of increasing the 
incubation duration of cells following transfection. Transfection efficiency was 
 32 
analysed at both 24 hr and 48 hr post-transfection. As shown in figure 2 E, incubating 
the cells for 48 hours resulted in a higher transfection efficiency (60%), compared to 
(45%) observed after 24 hours incubation. Accordingly, cells were incubated for 48 
hours in the following transfections. 
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Figure 2. Optimization of COBRA1 transfection in HepG2 cells 
The optimization of the transfection process is based on the percentage of the green florescent (pEGFP-
N1+) cells, RT-PCR and western blot analysis (A) Comparison between the transfection efficiency 
(pEGFP-N1+ cells) of reverse and forward transfection 24 hrs post transfection. The forward transfection 
resulted in an efficiency of 45% compared to 20% observed with the reverse transfection. (B) 
Lipofectamine volume. Two lipofectamine volumes of (3.75µl and 7.5 µl) were used and compared to 
their transfection efficiency based on the green florescent (pEGFP-N1+) cells. 45% transfection 
efficiency was obtained by using 3.75 µl lipofectamine in comparison to 30% obtained with 7.5 µl 
lipofectamine. (C) Comparison between the two lipofectamine volumes based on western blot analysis. 
(D) Comparison between the two lipofectamine volumes based on COBRA1 mRNA expression using 
semi-quantitative RT-PCR. The bands intensities in (C) and (D) were measured and normalized to their 
corresponding bands of the internal control (β-actin, β-tubulin) using image J software. (E) Incubation 
duration. Transfection efficiency was analysed at both 24 hr and 48 hrs post transfection and compared 
based on the green florescent (pEGFP-N1+) cells. Incubating the cells for 48 hrs resulted in a higher 
transfection efficiency (60%) compared to (45%) observed after 24 hrs incubation. 
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3.3. COBRA1 transfection efficiency and effect on cells morphology 
Upon using lipofectamine 3000 in the transfection, cells transfected with the pCM 
V5-HCOBRA1 plasmid showed a significant higher COBRA1 protein expression (P 
<0.001) compared to the control groups (Figure 3 A). Similarly, COBRA1 mRNA 
steady state expression was also significantly increased compared to the control groups 
as evidenced by the semi-quantitative RT-PCR (P<0.001) (Figure 3B). 
To determine whether COBRA1 overexpression alters the morphology pattern of 
HepG2 cells, photos of the pCMV5-HCOBRA1- transfected cells were compared to 
those obtained from the other control groups (pCMV5-empty-transfected, pEGFP.N1 
transfected and un-transfected cells). No significant difference in the cell morphology 
among all the tested groups was observed, indicating that COBRA1 doesn’t induce any 
morphological changes in HepG2 cells (Figure 4). 
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Figure 3. COBRA1 significantly overexpressed at both mRNA and protein levels  
(A) Western blot analysis of COBRA1 protein expression in pCMV5-HCOBRA1-transfected cells, 
relative to pCMV5-empty vector-transfected cells (B) Semi-quantitative RT-PCR analysis of COBRA1 
mRNA steady state expression in pCMV5-HCOBRA1- transfected cells, relative to pCMV5-empty-
transfected cells. A significant overexpression of COBRA1 on both mRNA and protein levels was 
observed. The intensities of the bands in (A) and (B) were measured then normalized to the loading 
control by image J software. Data represents the average ± SD of three independent experiments. 
Statistically significant at *** p < 0.001. (One-way ANOVA, Bonferonni’s post-test). 
 
 
 
Figure 4. The morphology pattern of HepG2 cells following COBRA1 overexpression.  
No changes on the cells morphology were observed following COBRA1 overexpression. Photos were 
obtained using phase contrast at 40X magnification. 
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3.4. mRNA and protein levels of the NELF subunits following COBRA1 
overexpression  
To determine whether COBRA1 overexpression influences the expression of the 
other NELF subunits, the mRNA levels of NELF-A, NELF-C/D and NELF-E were 
compared between COBRA1 transfected cells and the negative controls using RT-
PCR. As shown in figure 5 A, the mRNA levels of the three subunits showed 
comparable levels with no statistically significant difference noticed among them (P> 
0.05) (Figure 5A). Similarly, when examined by western blot analysis, no significant 
difference in NELF-E protein levels was noticed in pCMV5-HCOBRA1-transfected 
cells compared to the control groups (p > 0.05) (Figure 5B). 
 
Figure 5. The expression of NELF-A, NELFC/D and NELF-E subunits upon COBRA1 
overexpression 
HepG2 cells were transfected with pCMV5-empty vector, pCMV5-HCOBRA1, pEGFP-N1 or left un-
transfected. 48 hrs post transfection, cells were harvested and analysed for mRNA expressions of NELF-
A, NELF-C/D and NELF-E by the semi quantitative RT-PCR. (B) HepG2 cells were transfected with 
pCMV5-empty vector, pCMV5-HCOBRA1 or left un-transfected. 48 hrs post transfection, cells were 
harvested and analysed for the protein levels of NELF-E by western blot analysis. The intensities of the 
bands in (A) and (B) were measured then normalized to the loading control by image J software. Data 
represents the average ± SD of three independent experiments (one-way ANOVA, Bonferonni’s post-
test) (P>0.05). 
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3.5. TFF1 and TFF3 mRNA levels following COBRA1 overexpression  
Both TFF1 and TFF3 are known to be regulated by the NELF complex (S. Aiyar, 
Blair, Hopkinson, Bekiranov, & Li, 2007; S. E. Aiyar et al., 2004; Kininis, Isaacs, Core, 
Hah, & Kraus, 2009). To determine the effect of overexpressing COBRA1 on the levels 
of TFF1 and TFF3, the mRNA steady state levels of these genes were compared 
between the COBRA1 transfected cells and the non-transfected cells. Notably, no 
statistically significant difference in the mRNA levels of both TFF1 and TFF3 was 
noticed among all the groups (Figure 6). 
 
 
Figure 6. TFF1 and TFF3 expressions following COBRA1 overexpression  
(A) Semi-quantitative RT-PCR analysis of TFF1 mRNA levels in pCMV5-empty-transfected cells, 
pCMV5-HCOBRA1-tranfected cells, pEGFP-N1-tranfected cells and un-transfected cells. (B) Semi-
quantitative RT-PCR analysis of TFF3 mRNA levels in pCMV5-empty-transfected cells, pCMV5-
HCOBRA1-tranfected cells, pEGFP-N1-tranfected cells and un-transfected cells. The intensities of the 
bands in (A) and (B) were measured then normalized to the loading control by image J software. Data 
represents the average ± SD of three independent experiments. (One-way ANOVA, Bonferonni’s post-
test). (P>0.05).  
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3.6. COBRA1 overexpression effect on the proliferation potential of HepG2 cells 
To investigate if overexpressing COBRA1 can promote the cellular proliferation, 
the growth of cells transfected with either pCMV5-COBRA1 or pCMV5-empty vector 
was monitored for 4 days following transfection. 
COBRA1 transfected cells showed comparable proliferation rate compared to that 
of those transfected with the empty vector (Figure 7A). These results suggested that 
COBRA1 overexpression doesn’t have a proliferation endorsing role in HepG2 cells. 
To confirm this notion, we examined the expression of the proliferation marker, ki-67 
following COBRA1 overexpression. Ki-67 is known to be associated with cell 
proliferation. The presence of this protein in the nuclei of cells in the active phases of 
the cell cycle (G1, S, G2, and mitosis), in addition to its absence from the resting phase 
(G0), makes of it a good indicator of the cells growth and proliferation (Gerdes & 
Scholzen, 2000). No significant difference in ki-67 mRNA levels was observed in 
COBRA1-trnasfected cells when compared to the control cells as evidenced by semi-
quantitative RT-PCR (P >0.05) (Figure 7 B). 
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Figure 7. The proliferation potential of HepG2 cells following COBRA1 overexpression 
(A) Cell growth curve representing the growth of cells transfected with either pCMV5-HCOBRA1 or 
pCMV5-empty vector. HepG2 cells were transfected with the pCMV5-empty or pCMV5-HCOBRA1 
vector, harvested at 24, 48, 72 and 96 hrs post transfection, and counted using the trypan blue dye-
exclusion method. Data represents the average ± SD of three independent experiments (two-way 
ANOVA, Bonferonni’s post-test) (B) Semi-quantitative RT-PCR analysis of Ki-67 mRNA expression 
in pCMV5-empty-transfected cells, pCMV5-HCOBRA1-tranfected cells, pEGFP-N1-tranfected cells 
and un-transfected cells. The intensities of the bands were measured then normalized to the loading 
control by image J software. Data represents the average ± SD of three independent experiments. (One-
way ANOVA, Bonferonni’s post-test) (P>0.05).  
 
3.7. COBRA1 Overexpression effect on the migratory potential of HepG2 cells 
To examine if overexpressing COBRA1 can enhance the migration of HepG2 cells, 
the wound-healing assay was applied. Both pCMV5-HCOBRA1 and pCMV5-empty 
plasmids-transfected cells were compared according to their migration rates. Cells 
transfected with pCMV5-HCOBRA1 closed the scratch wounds at a higher rate than 
the cells transfected with the pCMV5-empty plasmid. However, the wound closure of 
both groups showed no statistically significant difference (P>0.05), with a wound 
closure percentage of 11.3% obtained for pCMV5-empty plasmid-transfected cells and 
15.5 % for pCMV5-HCOBRA1plasmid-transfected cells (Figure 8). 
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Figure 8. The migratory potential of HepG2 cells following COBRA1 overexpression.  
The wound healing assay was used to analyse the migration rate of HepG2 cells following COBRA1 
overexpression (A) Images of the wound areas taken at both 0 and 24 hrs times using phase contrast at 
10X magnification (B) The percentage of wound closure in pCMV5-HCOBRA1 transfected cells versus 
pCMV5-empty transfected cells. The open areas were measured using TScratch software followed by 
calculation of the percentage of wound closure. Data represents the average ± SD of three independent 
experiments. (Student t-test, two-tailed) (P>0.05). 
 
 
3.8. COBRA1 Overexpression effect on the survivin gene expression 
To determine if overexpressing COBRA-1 could affect the expression of genes 
known to be deregulated in cancer, RT-PCR was carried out to examine the mRNA 
expression of the survivin gene following COBRA-1 overexpression. The survivin 
gene is known to be deregulated in cancer, and was shown to play key roles in the 
survival and proliferation of cancer cells (Fukuda & Pelus, 2006). As shown in Figure 
9, upon COBRA1 overexpression, no statistically significant difference in the levels of 
the 3 survivin transcripts (survivin-2B, survivin-deltaex3 and the wild type survivin) 
was noticed compared to the control groups ( P>0.05). 
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Figure 9. survivin mRNA expression following COBRA1 overexpression.   
HepG2 cells were transfected with pCMV5-empty, pCMV5-HCOBRA, pEGFP-N1 or left un-
transfected. 48 hrs post transfection, total RNA was extracted and analysed for survivin mRNA 
expressions using semi quantitative RT-PCR. The intensities of the bands were measured then 
normalized to the loading control by image J software. Data represents the average ± SD of three 
independent experiments. (One-way ANOVA). 
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CHAPTER 4. DISCUSSION 
 
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related 
deaths worldwide, accounting for around 746,000 deaths annually(Flores & Marrero, 
2014). Despite the improvements in HCC therapy, almost 80% of the patients were 
reported to proceed to advanced stages with poor prognosis(C. Sun et al., 2013; Yin et 
al., 2012). Therefore, identifying the molecular mechanisms and biomarkers involved 
in HCC pathogenesis is essential for a better management of the disease. 
One of the biomarkers that was shown to be involved in HCC is Cofactor of BRCA1 
(COBRA1). Previous studies have demonstrated a potential role for COBRA1 in HCC 
pathogenesis (Youssef et al., 2016), and established a conceivable link between 
COBRA1 and several proteins known to be involved in tumorigenesis including cell 
proliferation and anti-apoptotic pathways (ElZeneini et al., 2016). In the current study, 
we extended the previous studies by elucidating the link between COBRA-1 
overexpression and HCC tumerogenesis. 
4.1. Co-dependent stability of the NELF subunits 
The multi-subunit negative elongation factor (NELF) complex consists of four 
subunits (NELF-A, NELF-B, NELF-C/D and NELF-E). It was reported that all of the 
four subunits are essential for the formation of the functional complex. Along with 
NELF C/D, NELF-B (COBRA1) acts as a core of the NELF complex to bring both 
NELF-A and NELF-E together, resulting in a functional complex (S. E. Aiyar et al., 
2004; Narita et al., 2003). This explains the interdependent manner by which the NELF 
complex works. In fact, several studies have previously reported a simultaneous 
recruitment of the NELF subunits upon the binding of COBRA-1 to its ER-α regulated 
target genes(S. E. Aiyar et al., 2004). 
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Our RT-PCR analysis results showed comparable mRNA expressions of the NELF 
subunits following COBRA1 overexpression. These results correlates with the 
previously suggested involvement of post transcriptional mechanisms in the regulation 
of the NELF complex interdependent expression(J. Sun et al., 2008). 
Following COBRA1 overexpression, the protein levels of NELF-E showed similar 
expressions with those observed in the control groups. These results are supported by 
another study, in which ectopic expression of COBRA-1 in T47D breast cancer cells 
resulted in an increase in the protein levels of COBRA1, with no change observed in 
the expression of the other NELF subunits(J. Sun et al., 2008). These findings indicate 
the tight control that governs the stability of the NELF complex under normal cellular 
perspectives. 
In light with the previously reported co-dependent regulation of the NELF complex, 
previous studies have reported a similar expression of different NELF subunits in the 
same cancer type. This was reported in breast cancer, where both NELF-B and NELF-
C/D were found to have decreased levels in the advanced breast cancer cells(J. Sun et 
al., 2008). This pattern was also observed in another study, in which both NELF-E and 
NELF-B were reported to be associated with the tumorigeneses of  gastrointestinal 
carcinoma (McChesney et al., 2006). Hence, it would be of interest to examine the roles 
of different NELF subunits in HCC development.  
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4.2. Trefoil factors (TFF1 & TFF3) expressions relative to COBRA1 
overexpression 
Trefoil factor family (TFF) members, TFF1 (pS2), TFF2 (SP) and TFF3 (ITF) are 
small mucin associated proteins that are highly conserved and tandemly clustered 
within a region of 55 kb on the human chromosome 21(Terada, Sakagami, Tabuchi, & 
MAEDA, 2001). They are normally expressed in the upper gastrointestinal tract. In 
fact, several studies have indicated the involvement of the trefoil factor family (TFF) 
genes in the gastrointestinal tract repair and defence mechanisms(Taupin, Kinoshita, & 
Podolsky, 2000; Terada et al., 2001).  
It was reported that both TFF1 and TFF3 are regulated by the NELF complex (S. 
Aiyar et al., 2007; S. E. Aiyar et al., 2004). In fact, previous studies have indicated that 
NELF-B (COBRA1) overexpression negatively regulates the expression of these genes 
(S. Aiyar et al., 2007; McChesney et al., 2006). Our findings showed a comparable 
mRNA levels of both TFF1 and TFF3 between COBRA1-transfected cells and non-
transfected cells. In this regard, it is vital to point out the functional entity by which the 
NELF complex modulate the gene expression. Previously, it was reported that 
COBRA1 mediated repression of ER-α controlled genes is dependent on the presence 
of other NELF subunits (S. E. Aiyar et al., 2004). Our results didn’t reveal an increase 
in the expression of the other NELF subunits upon COBRA1 overexpression. This 
suggests that COBRA1 mediated suppression of TFF1 and TFF3 expression is 
dependent on the expression of the other NELF subunits. Thus, we speculate that 
overexpressing the other NELF subunits is likely to significantly affect TFF1 and TFF3 
genes expression. 
Since there are many transcription-binding sites in the promoters of both TFF1 and 
TFF3 genes, it is also possible that the expression of these genes is influenced by other 
transcription factors beside the NELF complex. This notion is supported by another 
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study done on UGC cells. In this study, site-directed mutagenesis of the AP-1 complex 
binding sites, to which COBRA1 binds and controls the expression of TFF1, didn’t 
alter the expression of TFF1, indicating that TFF1 expression regulation is not 
exclusive to COBRA1  (McChesney et al., 2006). Furthermore, it is crucial to mention 
that in hepatic cancer, the regulation of TFF1 expression was reported to be mediated 
by estrogen stimulation (Barkhem, Haldosén, Gustafsson, & Nilsson, 2002; Jakacka et 
al., 2001). In fact, this regulation depends on the interaction between both the ER and 
the AP-1 complex. Thus, it is possible that COBRA1 regulation of TFF1 is dependent 
on both estrogen stimulation and AP-1 complex. Accordingly, we hypothesize that, 
because under the applied experimental conditions, estrogen was at its basal levels, 
COBRA1 regulation of TFF1 expression was altered, leading to the observed results. 
However, in order to confirm this notion, further studies should investigate whether 
estrogen treatment will enhance COBRA1 control of TFF expression. 
4.3. COBRA-1 overexpression effect on the proliferation potential of HepG2 cells 
One of the essential traits of cancer cells is their ability to sustain chronic 
proliferation. Hence, proliferation is considered as one of the main trademarks of 
cancer (Hanahan & Weinberg, 2011). Previously, COBRA1 involvement in the 
proliferation of different cancer types was reported. In breast cancer, a significant 
reduction of the proliferation of breast cancer cells was noticed following COBRA1 
Overexpression (S. E. Aiyar et al., 2004). In addition, the role of COBRA1 in ovarian 
cancer proliferation was reported. Pohl et al, 2005 have reported a noteworthy decrease 
in the proliferation of ovarian cancer cells upon the inactivation of the Ras/MAPK 
pathway. Being identified as one of the targets of this oncogenic pathway, COBRA1 
expression was also significantly downregulated (>3-fold)(Pohl et al., 2005). 
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Our results haven’t indicated any significant role of COBRA1 overexpression in 
enhancing the proliferation of HepG2 cells, as evidenced by both the cell growth and 
the ki-67 mRNA expression. These findings might appear somewhat unexpected, given 
that our group has previously demonstrated a significant decrease of HepG2 cells 
proliferation following COBRA1 knock-down (El Zeneini, 2016). This is most likely 
explained by the tight regulation of the NELF complex. In fact, previous studies have 
demonstrated an interdependent regulation of the NELF subunits, where a knockdown 
of any of the NELF subunits results in a co-depletion of the other NELF subunits(Narita 
et al., 2007; J. Sun et al., 2008). Thus, it is possible that upon knocking down NELF-
B, the proper formation of the NELF complex was hindered, resulting in an altered 
function of the complex and leading to the observed effect on the cells proliferation. 
This raises the possibility that COBRA1 role in the proliferation is dependent on its 
cooperation with the other NELF subunits, and that overexpressing NELF B is only 
part of the process of promoting the cells proliferation. Thus, it is conceivable that 
overexpressing the other NELF subunits would enhance the proliferation-activation 
ability of COBRA1. In fact, previous studies done on proteins that function within 
complexes, have indicated the importance of the assembly of all the complex subunits 
for a proper function of the protein. Wang et al. (2014) reported a similar proliferative 
phenotype upon both the knock-down and overexpression of one of the three subunits 
of the SR protein-specific kinase (SRPK) complex. This similar phenotype was  
explained by the improper assembly of the complex that has resulted in both 
cases(Wang et al., 2014). Taken together, our data support the notion that COBRA1 
overexpression alone is inadequate to promote HepG2 cells proliferation. 
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It is also worth pointing out that other regulatory pathways might be involved in 
COBRA1 regulation of the expression of proliferation markers like Ki-67. Nonetheless, 
further examinations are required before a conclusion could be drawn here. 
4.4. COBRA1 overexpression effect on the migratory potential of HepG2 cells  
Another fundamental trait of cancer cells is their ability to migrate from the primary 
tumour to other parts of the body, providing by this a good indicator of cancer 
progression and metastasis. Thus, studying the migratory potential of cancer cells is 
usually carried out to obtain a clear picture of the state of cancer progression and 
prognosis (Hanahan & Weinberg, 2011).  
The role of COBRA1 in the migration was previously shown in many cancer types 
including breast cancer. Sun et al, 2008 have reported a significant low levels in the 
advanced breast cancer cell lines, suggesting a strong association with metastatic breast 
cancer. These results go in line with the established role of COBRA-1 as a tumor 
suppressor in breast cancer(J. Sun et al., 2008). 
Here, the wound-healing assay was carried out to investigate COBRA1 
overexpression role in the migratory potential of HepG2 cells. Our results showed 
comparable migratory ability of COBRA1-transfected cells with that observed with the 
empty plasmid-transfected cells. These results oppose those made previously by our 
group, in which COBRA1- knockdown was found to significantly decrease the 
migratory potential of HepG2 cells (El Zeneini, 2016). This could be explained by the 
previously mentioned tight regulation of the NELF complex, which is likely to function 
properly within an interdependent manner. Thus, overexpression of COBRA1 alone is 
not enough to induce the migration of the cells. 
It is crucial to point out that our study was done using HepG2 cells, which represent 
early stages of HCC. Given that the migratory potential of cancer cells indicates the 
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metastasis and progression state of cancer, it will be worthwhile to include more cells 
that represent advanced stages of HCC. In this regard, it is worth mentioning that 
previously, our group have reported a higher migratory ability of the advanced stage-
HCC cells; SNU-449 compared to HepG2 cells(Youssef et al., 2016). 
4.5. COBRA1 overexpression effect on the mRNA expression of survivin 
survivin, one of the members of the inhibitor of apoptosis family (IAP), is known to 
have high expression levels in cancer compared to normal tissues (Ambrosini, Adida, 
& Altieri, 1997; Jaiswal, Goel, & Mittal, 2015). The high expression of survivin in 
cancer is mainly due to its anti-apoptotic activity as well as its involvement in the cell 
cycle progression. In fact, the expression of survivin is cell cycle-dependant. It has 
weak expression at the G1 phase, multiplied by 6 in the S phase and exceeding 40 in 
the G2/M phase (Boidot, Végran, & Lizard-Nacol, 2014). 
survivin is encoded by BIRC5, a 14.5 Kb gene that consists of 3 introns and 4 exons 
located in chromosome 17 (Altieri, 2003; Ambrosini et al., 1997). Beside encoding 
survivin, BIRC5 encodes four additional splice variants (survivin-2b, survivin-ΔEx3, 
survivin-3b and survivin-2a), resulting in variants with different functions (Caldas, 
Honsey, & Altura, 2005; Mahotka, Wenzel, Springer, Gabbert, & Gerharz, 1999). Until 
now, only WT survivin, survivin-ΔEx3 and survivin-2b functions have been identified. 
Both WT survivin and survivin-ΔEx3 were reported to have anti-apoptotic activity, In 
contrast, survivin-2b was found to have a pro-apoptotic activity (Conway et al., 2000). 
While WT survivin was found to have a role in the cell cycle regulation, both survivin-
2b and survivin-ΔEx3 weren’t found to have such a role (Noton et al., 2006). 
Our findings indicate that all of the three variants of survivin were detected, with a 
dominant expression observed in the WT survivin. These results are consistent with a 
previous publication, in which the WT survivin was the dominant mRNA transcript 
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among the other variants in HCC (Kannangai, Wang, Liu, Sahin, & Torbenson, 2005). 
In fact, this pattern of expression was also observed in other cancer types such as 
stomach carcinoma as well as cervical cancer(Krieg et al., 2002; Li, 2003).  
Previously, our group has demonstrated a suppression of the expression of survivin 
upon COBRA1 silencing. Here, our findings didn’t demonstrate any significant 
difference in the expression of survivin among all the tested groups. In this regard, it is 
valuable to point out that the activation of survivin is mediated by several transcription 
factors such as STAT3, KLF5 and DEC1(Boidot et al., 2014). In addition to these 
transcription factors, many signalling pathways were found to be involved in the 
regulation of survivin expression. Among these are the Phosphoinositide 3-
kinase(PI3K)/Akt pathway and the mitogen-activated protein kinase (MAPK) pathway 
(Dan et al., 2004). In fact, these regulators are activated by different stimuli. For 
instance, it was reported that the treatment of the SK-BR-3 breast cancer cells with 
EGF results in induction of the MAPK pathway,  increasing by this the expression of 
survivin (Peng et al., 2006). Thus, it is possible that COBRA1 regulation of survivin is 
mediated by several stimuli. Given this, we speculate that treating the cells with certain 
stimuli might induce COBRA1 regulation of survivin. Also, it would be of value to do 
a microarray analysis to identify COBRA1- regulated genes and specify their relation 
to survivin regulatory pathways. 
In light with the established notion that the expression of survivin is correlated with 
higher tumor grades(Takashima et al., 2005), it will be interesting to examine COBRA1 
effect on the survivin gene using advanced stages- HCC cells. It is also worth 
mentioning that there is an increasing evidence suggesting the involvement of post-
transcriptional pathways in regulating the expression of survivin (Li, 2003). Thus, it is 
possible that detecting survivin on the protein level might lead to more valuable results. 
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CONCLUSION 
 
As far as we know, this is the first study to examine the role of COBRA1 
overexpression in HCC. In summary, our findings showed that COBRA1 
overexpression didn’t alter the expression of the other NELF subunits, indicating a tight 
regulation of the NELF complex under normal cellular circumstances. 
The insignificant effect of COBRA1 overexpression on the expression levels of both 
TFF1 and TFF3 supports the involvement of the other NELF subunits in this regulation, 
and raises the possibility of the contribution of other transcription factors and 
regulatory pathways as well. 
Furthermore, our findings didn’t reveal a significant role of COBRA1 
overexpression on the proliferation and migration rates of HepG2 cells. These results 
suggest that COBRA1 role in mediating the growth and migration of HCC cells is 
dependent on the expression of the other NELF subunits, indicating the functional 
entity by which the NELF complex work. 
Taken together, this study might serve as a base for further investigation of the role 
of the NELF complex in the tumorigenesis of HCC. 
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FUTURE DIRECTIONS 
 
This study was limited by testing one type of HCC cells. Hence, in order to gain a 
complete picture of the role of COBRA1 in HCC, it will be of value to include more 
cells that represent different stages of HCC. In addition, analysing the cell cycle 
distribution as well as the apoptotic index will give more insight about the molecular 
mechanisms by which COBRA1 overexpression affect HCC. Moreover, Microarray 
analysis of COBRA1-regulated genes in HCC will assist in determining the regulatory 
pathways by which COBRA1 control HCC. 
Under the applied experimental conditions, the GFP-expressing vector used to 
determine the transfection efficiency was separate from the COBRA1-expressing 
vector. Thus, it is recommended to clone COBRA1 into the GFP-expressing vector to 
gain a more reliable view of the transfection efficiency. 
In light of the observation of the importance of the expression of all the NELF 
subunits in inducing the function of COBRA1, it will be worthy to examine the effect 
of overexpressing the other NELF subunits beside COBRA1 on both of the growth and 
migration of HCC cells. 
To further investigate the role of COBRA1 in the tumorigenesis of HCC, it will be 
of interest in the future to include invivo experiments.  
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